• Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Archive - RAS Dialogue

  • Ras–dependent Paracrine Cascades
    August 17, 2017, by Kenneth P. Olive

    Most pancreatic cancers are driven by mutant K-Ras genes, and comprise a minority of cancer cells in a densely fibrotic and highly secretory tumor microenvironment. Interrupting the paracrine cascades in pancreatic cancers may improve treatment.

    Continue Reading >

  • RAS and MYC: Co-conspirators in Cancer
    July 13, 2017, by Brittany L. Allen-Petersen and Rosalie C. Sears

    The transcription factor MYC is an important downstream target of mutated RAS genes in human cancers. Inhibiting post-translational modifications of MYC to decrease its transcriptional activity is a new strategy for treating RAS-driven cancers.

    Continue Reading >

  • Powering Off Cancer
    June 9, 2017, by Costas Lyssiotis

    The uncontrolled growth of cancers is dependent on altered metabolism. For example, many cancers are highly dependent on the altered metabolic reactions that occur in their mitochondria. New therapies that target these reactions are being tested.

    Continue Reading >

  • The Mutational Spectra of Cancer Genes in TCGA Data
    May 10, 2017, by Bob Stephens

    The Cancer Genome Atlas has catalogued mutations in more than 30 cancer types. The NCI RAS Initiative uses TCGA data to prioritize and inform its research objectives. The bar graphs show data for KRAS, HRAS, NRAS, BRAF, TP53, EGFR, PIK3CA, and PTEN.

    Continue Reading >

  • A Panel of Isogenic RAS-Dependent Cell Lines Developed at the Frederick National Laboratory
    April 6, 2017, by Rachel Bagni

    Mouse embryonic fibroblasts have been engineered to lack all RAS genes on demand. Then individual RAS genes can be introduced. Such cells allow effects of drugs to be tested with more precision.

    Continue Reading >